SeqOnce Biosciences
Chris Angermayer is the CEO and Co-Founder of SeqOnce Biosciences. Prior to SeqOnce, they served as the Director of Finance and Operations at SynTouch LLC, a robotic haptics technology start up. Before that, Chris was the Director of the Alternative Asset Group at Quoin Capital LLC, a boutique investment bank. Chris has also served as Institutional Business Development / Analyst at McComsey Asset and as Director - Institutional Advisory Group at Windward Capital Management, both hedge fund / RIAs. Chris began their career in 1996 as Vice President - Associate Portfolio Manager at Roxbury Capital Management, LLC and then served as Portfolio Manager / Analyst at Opus Investment Advisors, LLC from 2002 to 2006.
Chris Angermayer completed their BA at Loyola Marymount University in Political Science and Business. Chris then went on to get their Master of Business Administration from the University of Southern California - Marshall School of Business with a focus in Finance & Entrepreneurship. Afterwards, they completed a Genetics and Genomics Certificate from Stanford University.
James Gilmore - CCO & Co-Founder, Joseph P. Dunham - CSO & Co-Founder report to Chris Angermayer.
This person is not in any offices
SeqOnce Biosciences
SeqOnce Biosciences is a privately held company located in Pasadena, California. Its core competencies, which include enzymology, nucleic acid chemistry, sample processing, and manufacturing, have served as engines for innovation, development of intellectual property, and ongoing product development.